Bumped kinase inhibitors (BKIs) of Cryptosporidium parvum calcium-dependent protein kinase 1 (CpCDPK1) are leading candidates for treatment of cryptosporidiosis-associated diarrhea. Potential cardiotoxicity related to anti-human ether-à-go-go potassium channel (hERG) activity of the first-generation anti-Cryptosporidium BKIs triggered further testing for efficacy. A luminescence assay adapted for high-throughput screening was used to measure inhibitory activities of BKIs against C. parvum in vitro. Furthermore, neonatal and interferon γ knockout mouse models of C. parvum infection identified BKIs with in vivo activity. Additional iterative experiments for optimum dosing and selecting BKIs with minimum levels of hERG activity and frequencies of other safety liabilities included those that investigated mammalian cell cytotoxicity, C. parvum proliferation inhibition in vitro, anti-human Src inhibition, hERG activity, in vivo pharmacokinetic data, and efficacy in other mouse models. Findings of this study suggest that fecal concentrations greater than parasite inhibitory concentrations correlate best with effective therapy in the mouse model of cryptosporidiosis, but a more refined model for efficacy is needed.
The only Food and Drug Administration-approved therapy for cryptosporidiosis, nitazoxanide, was shown in a randomized trial to reduce the duration of diarrhea by approximately 2 days in immunocompetent individuals [8] . Nitazoxanide also has limited efficacy and a high failure rate in immunocompromised individuals [9] . It is not approved for use in children <12 months of age, whereas studies in malnourished children show poor response rate [10] . With the burden of disease falling disproportionately on young children in regions with a high human immunodeficiency virus prevalence [11] and widespread malnutrition, better drugs are needed for cryptosporidiosis therapy.
Multiple studies have shown that inhibition of apicomplexan calcium-dependent protein kinases (CDPKs) interfere with the parasites' ability to invade or egress mammalian host cells [12] [13] [14] . Calcium regulation in diverse metabolic and functional pathways is essential to apicomplexan parasites' survival [15] [16] [17] [18] . It has previously been demonstrated that C. parvum growth was inhibited by BKIs that target CpCDPK1 [19] . BKI 1294 exhibited anti-Cryptosporidium efficacy in the SCID/beige immunocompromised mouse and the newborn calf C. parvum clinical models [20, 21] . Since Cryptosporidium infections are predominant in the gastrointestinal tract, therapeutic agents with unconventional pharmacokinetic and pharmacodynamic properties may be required for effective treatment. Here we report our progress to identify BKIs that are effective against Cryptosporidium.
UGA1 transfected to express nanoluciferase (Nluc) [24] , purification of oocysts from fecal specimens [23, 25] , synthesis of BKIs [19, 26, 27] , measurement of in vitro CpCDPK1 activity [19] , pharmacokinetic analysis of plasma and fecal BKI concentrations [15, 21] , in vitro investigation of BKI plasma protein binding [28] , and determination of BKI efficacy in neonatal mice [21] and adult SCID/beige mice [20] have been previously described. Variances from published procedures are included in the Supplementary Materials and Methods.
C. parvum Growth Inhibition by BKIs
Assays to determine growth inhibition and the 50% effective concentration (EC 50 ) were performed using a C. parvum strain UGA1 expressing Nluc in human ileocecal adenocarcinoma (HCT-8) cells (ATCC, Manassas, VA) as previously described [24] with the following modifications. HCT-8 cells were inoculated onto 96-well plates and allowed to grow for 48 hours to 90%-100% confluence. C. parvum oocysts were incubated for 10 minutes in 10% bleach at room temperature and washed with Dulbecco's phosphate-buffered saline. One thousand oocysts per well were applied to plates with Roswell Park Memorial Institute 1640 (RPMI) medium supplemented with 10% horse serum and 1% penicillin/streptomycin at the same time as compound addition and incubated for 48 hours. The monolayers were lysed for 1 hour before Nano-Glo luciferase reagent (Promega, Madison, WI) was added, and relative luminescence units (RLU) were determined on an EnVision Plate Reader (Perkin Elmer, Waltham, MA). EC 50 values were calculated using Prism (GraphPad, La Jolla, CA). Assays were repeated 2-3 times, and representative data are expressed as means ± standard deviation.
Efficacy in Adult Interferon γ (IFN-γ) Knockout (KO) Mice
Female IFN-γ KO mice (B6.129S7-Ifngtm1Ts/J, Jackson Laboratories) aged 8-10 weeks were infected by oral gavage with 1000-10 000 C. parvum UGA1 oocysts carrying Nluc in 0.1 mL of Dulbecco's phosphate-buffered saline. Beginning on day 3 or 6 after infection, mice were dosed orally with BKI suspended in 0.2 mL of oral vehicle (3% ethanol/7% Tween 80/90% saline) or vehicle only once daily for 5 days. Mice were moved to clean cages after each dose and fecal collection. Fecal specimens were collected daily and weighed from each group during dosing and twice weekly out to 20-21 days after infection. Each fecal sample was checked for luminescence on the day of collection [24] , and RLU readings were normalized to fecal sample weights. For subcutaneous doses, the vehicle was 60% Phosal 53 MCT/30% PEG/10% ethanol, as oral vehicle can cause inflammation when injected (unpublished data). GraphPad Prism was used to determine the statistical significance of outcomes, using the Student t test and the correlation coefficient (8) for efficacy, with respect to systemic exposure (as measured by the area under curve [AUC]) and fecal concentrations.
Animal Ethics Statement
All animal experiments were approved by the institutional animal care and use committees at the participating universities (University of Washington, University of Georgia, University of Arizona, and University of Texas Medical Branch).
RESULTS
Lead BKIs were selected as potential Cryptosporidium therapies on the basis of favorable in vitro parameters, including c-Src off-target effects, mammalian cytotoxicity, hERG activity, and efficacy in the HCT-8 infection model (Table 1 and Figure 1A ). Select lead candidates were evaluated for efficacy in neonatal mice and in plasma and fecal specimens from adult mice after oral dosage. BKIs were also eliminated on the basis of efficacy or exposure findings that approached or exceeded hERG or toxicity levels, as indicated by the in vitro results (Tables 1  and 2 and Figure 1A ). Adult mouse efficacies were evaluated for all remaining BKIs, with analyses of efficacious compounds repeated to determine their effect at different treatment times, concentrations, and dose administrations (Figures 1-3 ).
Enzymatic and Cellular Potency and Off-Target Cytotoxicity
The BKIs described here were tested for the inhibition of recombinant CpCDPK1 activity ( Table 1 ). All BKIs were counter-screened against the mammalian tyrosine kinase c-Src and screened for mammalian cytotoxicity in vitro to eliminate toxic compounds. BKIs with activity against c-Src were eliminated because of concerns about off-target inhibition of mammalian kinases [29] . BKI 1294 had previously been reported to inhibit hERG at concentrations needed for efficacy, and hERG is a cardiotoxicity liability to be avoided [27, 30] . Accordingly, the remaining BKIs were screened for hERG inhibition by the thallium-flux assay for potassium channels [31, 32] . The BKIs listed in (Table 1 ) have a ≥10 fold higher hERG 50% inhibitory concentration (IC 50 ) than BKI 1294 and thus have less potential for cardiotoxicity.
In Vitro Inhibition of Cryptosporidium Growth by BKIs
Nluc-expressing C. parvum oocysts were used to infect HCT-8 cells to assay for cellular BKI inhibition [24] . Compounds with an IC 50 of >0.10 μM against recombinant CpCDPK1 enzyme showed little or no activity against the parasites in vitro, whereas compounds with a CpCDPK1 IC 50 of <0.020 µM inhibited Cryptosporidium proliferation in the low micromolar range (Table 1 ). BKIs RM-1-22, RM-1-89, 1243, 1266, 1416, 1610, and 1624 were all eliminated from further examination because of poor activity, off-target c-Src inhibition, or mammalian cell cytotoxicity ( Figure 1B BKIs were tested in a neonatal mouse model of C. parvum infection at an oral dose of 25 mg/kg given twice daily. For all compounds, infection levels decreased by 14%-76% relative to levels after vehicle treatment ( Table 1 ). The least effective BKI in this series, 1412, reduced oocyst shedding by a level similar to that for paromomycin (Table 1) . BKIs 1556, 1649, and 1663 showed signs of toxicity-specifically, protruding sternums-in infected neonatal mice. Although it is not intended to evaluate toxicity, the neonatal mouse model is practical for investigation and interpretation of data for various aspects of cryptosporidiosis in human infants, including potential harm from drug treatment. For this reason and its hERG-associated liability (Table 1) , 1663 was eliminated from further consideration ( Figure 1B ). Compounds 1412, 1546, 1553, and 1557 were eliminated because of suboptimal efficacy in neonatal mice, defined as a <50% reduction of infection levels ( Figure 1B ).
BKI Levels in Mouse Plasma and Feces
Plasma and stool drug levels were determined after oral dosing in adult mice (Table 2) . BKI 1556 was eliminated because its high oral exposure led to a concern that it would reach hERG-inhibiting plasma concentrations (Table 1 and Figure 1B ). BKI 1649 was further evaluated at doses of <25 mg/kg twice daily, because 25 mg/kg twice daily was toxic in infected neonatal mice.
BKI Efficacy in the IFN-γ KO Mouse Model of C. parvum Infection
It is not yet clear which mouse model of Cryptosporidium infection predicts effective therapy in humans. In the IFN-γ KO mice model, infection is progressive, whereas immunocompetent neonatal mice are transiently infected for 10 days before the infection is cleared [24] . BKIs 1266, 1294, 1318, 1369, 1534, 1550, and 1649 were delivered orally for 5 days beginning at day 3 after infection ( Figure 2A and 2B). Compound 1266 (CpCDPK1 IC 50, 0.58 µM; C. parvum EC 50 , >80 µM) was included as a negative control and showed no clearance of C. parvum, compared with untreated controls (Figure 2A ). In contrast, BKIs 1294, 1369, and 1534 significantly reduced parasite shedding (P < .002; Figure 2A and 2B). BKIs 1550 and 1318 (P < .5 for both) only slightly reduced the parasite load and were eliminated from further consideration ( Figure 2B ). BKI 1649 was delivered at a dose of 6 mg/kg/day, owing to its high oral exposure (Table 2 ) and neonatal mouse toxicity at 25 mg/kg twice daily, and still significantly reduced infection (P < .01) and was therefore worthy of further evaluation.
No clinical signs of illness were observed in the infected IFN-γ KO mice, except for gradual weight loss and decreased activity in control and unsuccessfully treated mice. Infection intensities varied between the different IFN-γ KO mouse experiments. This can be observed by higher fecal luciferase levels in the second experiment ( Figure 2B ). The control mice referenced in ( Figure 2B ) lost ≥20% of their baseline body weight-the threshold at which euthanasia is required-by 20 days after infection, unlike the control mice referenced in (Figure 2A ), where this threshold was not reached by the end of the experiment. The increased infection level was associated with relapsed oocyst shedding after the completion of dosing in some experiments. BKI 1294 administration consistently led to a significant reduction of infection, but a recurrent increase in parasite excretion was observed ( Figure 2B ). This was different than the initial experiment, in which no recurrent increase was noted with the same dose ( Figure 2A ). The greater relapse in the A-C, Efficacies against C. parvum excretion in adult interferon γ knockout mice, based on nanoluciferase activity log RLU plotted on y-axis (A-C), and efficacy of BKI 1534 in SCID/beige mice, using reverse transcription-polymerase chain reaction to quantify infection (8) . A, BKIs were delivered orally for 5 days, beginning 3 days after infection. In vivo inhibition by BKIs 1266, 1294, 1534, and 1550. BKI 1266, with limited inhibition of the C. parvum calcium-dependent protein kinase 1 target enzyme, was included as a negative control. BKIs 1294 and 1534 significantly reduced parasite shedding as compared to controls. The C. parvum infectious dose was 10 000 oocysts. B and C, Significant initial reduction of parasite burden by BKIs, even in the case of higher fecal luciferase levels, which reflect higher parasites load. Parasite excretion rebounds when control animals show a higher infectious burden (8) . BKIs 1294 (100 mg/kg once daily), 1369 (100 mg/kg once daily or 50 mg/kg twice daily), and 1649 (10 mg/kg once daily) efficacies (uninfected control mice had the highest recorded levels; C). BKIs substantially reduced Cryptosporidium proliferation, as shown by lower oocyst counts. A once-daily BKI 1369 dose of 100 mg/kg significantly reduced the infection burden (by 100 000-fold), relative to that in untreated controls. BKI 1649 was administered at lower doses than other compounds owing to its high oral exposure, but it still significantly reduced infection relative to controls. The C. parvum infectious dose was 1000 oocysts. D, BKI 1534 delivered orally at a dose of 60 mg/kg for 5 days cleared infection with no recurrence.Assays were performed at the University of Georgia (Athens; A), second experiment as compared to the first may have been due to the increased infection level, judging by the more rapid onset of infection and higher levels of luciferase signal. A recurrent rise in infection level was also observed after BKI 1369 treatment ( Figure 2B ), again perhaps due to the increased infection level. However, the level of infection after treatment remained at <15% of that for controls, and the mice appeared healthy for the duration of the experiment. The efficacies of BKIs 1294, 1369, and 1649 were tested at higher oral doses ( Figure 2C ). BKI 1369 was administered at 100 Figure 3 . Efficacy in adult interferon γ knockout mice with dosing starting on day 6 after infection. In all mice, the nanoluciferase-expressing Cryptosporidium parvum infectious dose was 1000 oocysts. A, Efficacy plots of bumped-kinase inhibitors (BKIs) 1294, 1369, 1534, and 1649 used for treatment of highly established infection when administered orally at 60 mg/kg once daily for 5 days. BKI 1649 was administered at 6 mg/kg once daily. All BKIs showed significant decreases in infection. B, Efficacy of subcutaneous versus oral dosing of mice with 1294 at 60 mg/kg, starting on day 6 after infection, for 5 days. BKI 1294 showed a significantly greater reduction in oocyst excretion when delivered orally as compared to an equivalent dose delivered subcutaneously (P < .05). This is probably due to a fecal concentration of orally administered 1294 that was higher than the 50% effective concentration (EC 50 ) early in the treatment period and to the longer presence of the orally administered 1294 in the lumen relative to the subcutaneously administered dose, for which the level after a single dose was below the EC 50 . C, Efficacy of subcutaneous versus oral dosing with 1534 at 60 mg/kg, starting on day 6 after infection, for 5 days. No significant difference was seen in parasite excretion between the groups receiving the BKI doses. mg/kg orally once daily or at 50 mg/kg orally twice daily, and BKI 1649 was delivered at 10 mg/kg orally once daily. Compound 1294 was included at 100 mg/kg orally once daily. The infection in this experiment was even more robust, with parasite loads in control mice rising to their highest recorded levels. The control mice had weight loss requiring euthanasia at day 13 after infection, a week earlier than the experiment described in Figure 2B . This infection intensity probably led to BKI 1294 having less apparent efficacy ( Figure 2C ) than in previous experiments (Figure 2A and 2B) , while still significantly reducing infection (P < .05). Nonetheless, all BKIs had a substantial effect on infection ( Figure 2C) . BKI 1369 at 100 mg/kg once daily significantly reduced the infection (P < .05) to levels >100 000 times lower than those in controls. BKI 1369, when administered at 50 mg/kg twice daily, considerably reduced infection levels (P < .05) but with a faster recurrence and greater total oocyst excretion, compared with the same total dose given once daily. BKI 1649 also significantly reduced infection levels (P < .05) at a dose of 10 mg/kg once daily.
SCID/Beige Mouse C. parvum Model
BKI 1534 was tested in the SCID/beige mouse C. parvum infection model. BKI 1534 given orally at 60 mg/kg for 5 days cleared the infection, with no recurrence ( Figure 2D ).
BKI Therapy of Highly Established Infection in the IFN-γ KO Mouse

C. parvum Model
To test the effects of BKIs on higher infection levels, we evaluated the efficacy of our lead inhibitors by delaying dosing to day 6 after infection in IFN-γ KO mice. BKIs 1294, 1369, and 1534 were administered orally at 60 mg/kg once daily and BKI 1649 at 6 mg/kg once daily for 5 days. BKIs 1294 (P < .001), 1369 (P < .001), 1534 (P < .005), and 1649 (P < .001) all showed a significant decrease in the infection level ( Figure 3A) .
Comparison of Subcutaneous Versus Oral Administration of BKIs
It is unclear whether the optimal anti-Cryptosporidium agent should be absorbed systemically and/or retained in the gastrointestinal tract [33] . To evaluate subcutaneous administration, a single 60 mg/kg dose of BKI 1294 or 1534 was administered to uninfected mice. Plasma and fecal levels were measured and compared to oral dose pharmacokinetics (Tables 2 and  3 ). Subcutaneous delivery of BKI 1294 and 1534 resulted in higher systemic exposure and lower fecal concentrations than oral delivery, even when considering the different doses administered (10 mg/kg orally vs 60 mg/kg subcutaneously in single-dose pharmacokinetics analyses). To compare the efficacy of subcutaneous versus oral dosing, mice were given BKI 1294 or 1534 at 60 mg/kg once daily orally or subcutaneously for 5 days, starting on day 6 after infection ( Figure 3B and 3C) . Fecal specimens were collected 24 hours after the fifth dose, to measure BKI concentrations ( Table 3 ). The fecal concentration of BKI 1294 was only marginally higher after the fifth dose delivered subcutaneously, compared with the pharmacokinetics of the subcutaneously delivered single dose, while the fecal concentration of BKI 1534 was >10-fold higher after subcutaneous delivery of the fifth dose, compared with pharmacokinetics of the single dose administered subcutaneously (Table 3) . BKI 1294 showed a significantly greater reduction in infection when delivered orally, compared with an equivalent dose delivered subcutaneously (P < .05; Figure 3B ). However, BKI 1534 did not show a significant difference in parasite excretion between groups dosed orally and subcutaneously ( Figure 3C ).
DISCUSSION
A challenge to the development of effective therapy for Cryptosporidium infection is the differential efficiency of parasite clearance in various in vitro and in vivo models [37, 38] . A number of drug candidates have shown good inhibitory activity in vitro but have demonstrated low potency in clinical models and were not further considered [39] [40] [41] . In addition to C. parvum's natural resistance to many drug therapies, its characteristic subcellular location on the apical-surface of mammalian intestinal epithelium cells may constitute a barrier to effective drug delivery, preventing drugs from reaching therapeutic concentrations in the parasite [42, 43] . This provides the rationale for targeting enzymes such as CpCDPK1 that phenotypically affect extracellular stages.
Recently, a lack of correlation between anti-Cryptosporidium and CpCDPK1 enzyme inhibition for some pyrazolo [2,3-d] pyrimidine (PP) compounds was reported, suggesting potential alternative-target activity [34] . The observed c-Src activity for some BKIs supports this potential for off-target kinase activity. BKI 1243 does not have a bumped R1 aryl substituents at the C-3 position. For all other BKIs used in this study, especially with bumped R1, which project into CpCDPK1's enlarged glycine gatekeeper hydrophobic pocket, there is a statistically significant correlation between the CpCDPK1 IC 50 and the C. parvum cellular EC 50 (r 16 = 0.93; P < .0001). This suggests that the R1 groups are important in keeping these PP BKIs on target (Figure 4) . Additionally, antisense methods were recently used to reduce CpCDPK1 expression [35, 36] . These experiments demonstrated that knocking down expression of CDPK1 significantly decreased parasite invasion and growth, and there was an additive effect with BKIs in reducing the proliferation of C. parvum parasites for BKIs 1294 (PP) and 1517 (an aminopyrazole-carboxamide compound) [36] . This potentiation of BKI activity when CpCDPK1 expression is reduced is further evidence that CpCDPK1 is a target of our BKIs.
Further chemical-genetic validation experiments are needed to test the hypothesis that CpCDPK1 is the primary target of our selective BKIs.
There is an observed difference between EC 50 values against C. parvum in vitro determined using a reverse transcriptionquantitative polymerase chain reaction (RT-qPCR) assay [20, 36] and those determined by the Nluc assay reported here. This could be attributed to the end point readout of the RT-qPCR assay: RNA may degrade faster than the luciferase protein used in the Nluc assay. Thus, delayed degradation of luciferase protein could underestimate compound potency, compared with that determined by RT-qPCR. Nevertheless, luminescence readouts from Nluc-expressing C. parvum have been previously demonstrated to correlate with the level of oocyst shedding determined by real-time qPCR using 18S ribosomal RNA primers and DNA extracted from fecal material [24] .
The hERG IC 50 of 10 µM for BKI 1369 was initially a reason for concern in using the compound in humans. Previous studies of hERG suggests that the risk of arrhythmia is reduced for most drugs if the hERG IC 50 is >30-fold higher than the effective free therapeutic plasma concentration [47] . BKI 1369 displayed a maximum concentration of 0.26 μM at 10 mg/kg, which was 40-fold less than its hERG IC 50 . Additionally, BKI 1369 is 76% protein bound in human plasma ( Table 1) . The low maximum concentration and unbound fraction of BKI 1369 should mitigate the risks of hERG inhibition [47] . BKI 1294 was efficacious in SCID/beige mice [20] and neonatal mice (Table 1) and had significant therapeutic effects in the calf clinical model of cryptosporidiosis [21] . The efficacy of BKI 1294 was also demonstrated using IFN-γ KO mice infected with Nluc-expressing C. parvum. BKI 1294 was associated with relapses after treatment in both SCID/beige [20] and IFN-γ KO mouse models. In contrast, no relapses were detected with BKI 1534. The congruence of results across models supports the validity of the IFN-γ KO model for drug development purposes. A likely explanation for recrudescence, especially after high levels of infection are cleared, is the limited immunological resistance of this mouse strain. They will readily reinfect themselves, owing to factors such as oocysts on fur or cage bedding. It is therefore impossible to determine whether infections are recurring because of incomplete clearance or reinfection from grooming, coprophagy, or exposure to fecal matter from cohabitating mice. Future exploration into whether these BKIs will maintain their highly efficacious results in larger mammals is warranted.
Differences in efficacy between the neonatal and immunocompromised adult mice were observed for some compounds, including BKIs 1318 and 1550, which could be due to a number of reasons. These include the transient neonatal versus chronic IFN-γ KO infection and differential physiological characteristics relating to insufficiently developed neonatal organ-specific drug transporters and metabolic systems that may affect drug absorption, distribution, and elimination [44] [45] [46] . Furthermore, BKIs tested showed a lack of association between neonatal efficacy and plasma or fecal exposure in adult mice. Nonetheless, intraspecies metabolic barriers may have limited impact on the therapeutic outcome for treatment of cryptosporidiosis with BKIs, based on successful results of recent calf and SCID/beige mouse investigations [20, 21, 35] .
In IFN-γ KO mice, there is a lack of correlation between BKI systemic exposure (AUC) and Cryptosporidium efficacy (r 5 = -0.02; P < 1). In contrast, BKIs with high fecal concentrations (Table 2) were efficacious. BKIs 1318, 1550, 1553, and 1649 display the largest plasma AUCs of all compounds tested, yet BKI 1649 proved to be the only compound that was efficacious. BKIs 1318 and 1550 failed to significantly lower infection levels in IFN-γ KO mice, and BKI 1553 was the least effective compound of those tested in neonatal calves [21] . All 3 BKIs showed fecal concentrations in mice below their respective 50% effective concentrations (Table 1) . However, the fecal concentration of BKI 1649 was much higher at 5.76 µM ( Table 2 ). All other BKIs tested that had higher fecal concentrations, including BKIs 1294 (4.4 µM), 1369 (5.2 µM), and 1534 (10.1 µM), were efficacious in mice despite low systemic exposures. This demonstrates that PP-BKI fecal levels correlate with efficacy against Cryptosporidium organisms (r 5 = 0.78; P < .05), in line with the fact that infections localize at the lumen interface within the gut [42, 48] . Since fecal levels are imperfect estimators of exposure in the gastrointestinal tract, future studies are necessary to examine properties beyond plasma and fecal levels to thoroughly explain the pharmacodynamics of successful therapies for cryptosporidiosis.
For efficacy comparison between oral and subcutaneous doses, the BKI 1294 fecal concentration after the fifth dose was similar to its value after a single dose (Table 3 ). Fecal exposure of BKI 1294 given subcutaneously was around 1 µM, well below the 50% effective concentration for this compound. This offers a possible explanation for the subcutaneous dose being less efficacious than the equivalent oral dose. For BKI 1534, the fecal concentration appeared to rise, with pharmacokinetic analysis of the subcutaneously delivered single dose yielding a concentration of 0.44 µM, compared with 4.76 µM after the fifth dose (Table 3 ). This potentially explains the lack of significant difference between subcutaneous and oral delivery of BKI 1534 in reducing infection, as subcutaneous administration showed that the BKI concentration in feces increased to therapeutic levels by the end of dosing. This could provide an advantage over BKI 1294 in species for which oral dosing is difficult. Also, the hERG-associated liability is significantly reduced for BKI 1534 (25 µM) as compared to BKI 1294 (0.76 µM). Overall, the 2 compounds are equally efficacious in this mouse model. Given the localization of Cryptosporidium infection in the gastrointestinal tract in immunocompetent hosts but biliary and respiratory sites in immunocompromised hosts [49, 50] , some systemic absorption is important for optimal efficacy. Further investigations of different dosing routes and formulations are needed, especially in terms of systemic as compared to gastrointestinal exposure.
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